Cargando…

Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis

BACKGROUND: Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alshehri, Abdullah, Chhonker, Yashpal S., Bala, Veenu, Edi, Constant, Bjerum, Catherine M., Koudou, Benjamin G., John, Lucy N., Mitjà, Oriol, Marks, Michael, King, Christopher L., Murry, Daryl J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234547/ https://www.ncbi.nlm.nih.gov/pubmed/37262040 http://dx.doi.org/10.1371/journal.pntd.0011319

Ejemplares similares

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis
por: Chhonker, Yashpal S., et al.
Publicado: (2023)

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
por: Edi, Constant, et al.
Publicado: (2019)

A simple, high‐throughput and validated LC–MS/MS method for the determination of azithromycin in human plasma and its application to a clinical pharmacokinetic study
por: Zhang, Yuning, et al.
Publicado: (2022)

LC–MS/MS method for simultaneous determination of diethylcarbamazine, albendazole and albendazole metabolites in human plasma: Application to a clinical pharmacokinetic study
por: Chhonker, Yashpal S., et al.
Publicado: (2018)

Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d’Ivoire: A randomized controlled superiority study
por: Bjerum, Catherine M., et al.
Publicado: (2023)

Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019)

A Concise Review of Liquid Chromatography-Mass Spectrometry-Based Quantification Methods for Short Chain Fatty Acids as Endogenous Biomarkers
por: Trivedi, Neerja, et al.
Publicado: (2022)

Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS
por: Chhonker, Yashpal S., et al.
Publicado: (2018)

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial
por: Laman, Moses, et al.
Publicado: (2022)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

Lymphatic Filariasis Control in Tanzania: Effect of Repeated Mass Drug Administration with Ivermectin and Albendazole on Infection and Transmission
por: Simonsen, Paul E., et al.
Publicado: (2010)

Impact of Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages in Kongwa District, Tanzania
por: Martin, Diana, et al.
Publicado: (2018)

Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018–2019
por: Willis, Gabriela A., et al.
Publicado: (2023)

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
por: Tavul, Livingstone, et al.
Publicado: (2022)

Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission
por: Simonsen, Paul E, et al.
Publicado: (2013)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

Diversity and transmission competence in lymphatic filariasis vectors in West Africa, and the implications for accelerated elimination of Anopheles-transmitted filariasis
por: de Souza, Dziedzom K, et al.
Publicado: (2012)

Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso
por: Nikièma, Achille S., et al.
Publicado: (2021)

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis
por: Jambulingam, Purushothaman, et al.
Publicado: (2022)

Simultaneous Quantitation of S(+)- and R(−)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC–APCI–MS/MS: An Application for Clinical Studies
por: He, Qingfeng, et al.
Publicado: (2020)

Mapping lymphatic filariasis in Loa loa endemic health districts naïve for ivermectin mass administration and situated in the forested zone of Cameroon
por: Beng, Andrew A., et al.
Publicado: (2020)

MDA—Lymphatic Filariasis
por: Ichimori, Kazuyo
Publicado: (2014)

Urban lymphatic filariasis
por: Simonsen, Paul E., et al.
Publicado: (2012)

Correction: Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania
por: Fimbo, Adam M., et al.
Publicado: (2020)

Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study
por: Fimbo, Adam M., et al.
Publicado: (2022)

Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa
por: Wanji, Samuel, et al.
Publicado: (2018)

A Simultaneous Extraction/Derivatization Strategy for Quantitation of Vitamin D in Dried Blood Spots Using LC–MS/MS: Application to Biomarker Study in Subjects Tested for SARS-CoV-2
por: Chhonker, Yashpal S., et al.
Publicado: (2023)

Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria
por: Pam, Dung D., et al.
Publicado: (2017)

Mathematical study of the dynamics of lymphatic filariasis infection via fractional-calculus
por: Alshehri, Ahmed, et al.
Publicado: (2023)

Endpoints for Lymphatic Filariasis Programs
por: Grady, Caroline A., et al.
Publicado: (2007)

Mapping of lymphatic filariasis in Nepal
por: Sherchand, Jeevan B, et al.
Publicado: (2003)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Simultaneous Quantitation of Lipid Biomarkers for Inflammatory Bowel Disease Using LC–MS/MS
por: Chhonker, Yashpal S., et al.
Publicado: (2021)

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d’Ivoire
por: Loukouri, Agodio, et al.
Publicado: (2020)

Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination
por: Ghosh, Raj Shankar, et al.
Publicado: (2022)

A Selective and Sensitive LC-MS/MS Method for Quantitation of Indole in Mouse Serum and Tissues
por: Joshi, Vineet, et al.
Publicado: (2022)

National Mass Drug Administration Costs for Lymphatic Filariasis Elimination
por: Goldman, Ann S., et al.
Publicado: (2007)

Elimination of lymphatic filariasis: current perspectives on mass drug administration
por: Gyapong, John O, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pofiqnbqn4djqbrdtmtat35nbg